Estimating the impact of adopting the revised United Kingdom acetaminophen treatment nomogram in the U.S. population

Michael Levine, Sam Stellpflug, Anthony F. Pizon, Stephen Traub, Rais Vohra, Timothy Wiegand, Nicole Traub, David Tashman, Shoma Desai, Jamie Chang, Dhruv Nathwani, Stephen Thomas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Acetaminophen toxicity is common in clinical practice. In recent years, several European countries have lowered the treatment threshold, which has resulted in increased number of patients being treated at a questionable clinical benefit. Objective: The primary objective of this study is to estimate the cost and associated burden to the United States (U.S.) healthcare system, if such a change were adopted in the U.S. Methods: This study is a retrospective review of all patients age 14 years or older who were admitted to one of eight different hospitals located throughout the U.S. with acetaminophen exposures during a five and a half year span, encompassing from 1 January 2008 to 30 June 2013. Those patients who would be treated with the revised nomogram, but not the current nomogram were included. The cost of such treatment was extrapolated to a national level. Results: 139 subjects were identified who would be treated with the revised nomogram, but not the current nomogram. Extrapolating these numbers nationally, an additional 4507 (95%CI 3641–8751) Americans would be treated annually for acetaminophen toxicity. The cost of lowering the treatment threshold is estimated to be $45 million (95%CI 36,400,000–87,500,000) annually. Conclusions: Adopting the revised treatment threshold in the U.S. would result in a significant cost, yet provide an unclear clinical benefit.

Original languageEnglish (US)
Pages (from-to)569-572
Number of pages4
JournalClinical Toxicology
Volume55
Issue number6
DOIs
StatePublished - Jul 3 2017

Fingerprint

Nomograms
Acetaminophen
Health Care Costs
Population
Toxicity
Costs
Costs and Cost Analysis
Therapeutics
Delivery of Health Care
United Kingdom

Keywords

  • acetaminophen
  • Cost
  • paracetamol
  • Rumack–Matthew nomogram
  • toxicity

ASJC Scopus subject areas

  • Toxicology

Cite this

Estimating the impact of adopting the revised United Kingdom acetaminophen treatment nomogram in the U.S. population. / Levine, Michael; Stellpflug, Sam; Pizon, Anthony F.; Traub, Stephen; Vohra, Rais; Wiegand, Timothy; Traub, Nicole; Tashman, David; Desai, Shoma; Chang, Jamie; Nathwani, Dhruv; Thomas, Stephen.

In: Clinical Toxicology, Vol. 55, No. 6, 03.07.2017, p. 569-572.

Research output: Contribution to journalArticle

Levine, M, Stellpflug, S, Pizon, AF, Traub, S, Vohra, R, Wiegand, T, Traub, N, Tashman, D, Desai, S, Chang, J, Nathwani, D & Thomas, S 2017, 'Estimating the impact of adopting the revised United Kingdom acetaminophen treatment nomogram in the U.S. population', Clinical Toxicology, vol. 55, no. 6, pp. 569-572. https://doi.org/10.1080/15563650.2017.1291945
Levine, Michael ; Stellpflug, Sam ; Pizon, Anthony F. ; Traub, Stephen ; Vohra, Rais ; Wiegand, Timothy ; Traub, Nicole ; Tashman, David ; Desai, Shoma ; Chang, Jamie ; Nathwani, Dhruv ; Thomas, Stephen. / Estimating the impact of adopting the revised United Kingdom acetaminophen treatment nomogram in the U.S. population. In: Clinical Toxicology. 2017 ; Vol. 55, No. 6. pp. 569-572.
@article{ae55f47695504f0db63eec20853d25ac,
title = "Estimating the impact of adopting the revised United Kingdom acetaminophen treatment nomogram in the U.S. population",
abstract = "Background: Acetaminophen toxicity is common in clinical practice. In recent years, several European countries have lowered the treatment threshold, which has resulted in increased number of patients being treated at a questionable clinical benefit. Objective: The primary objective of this study is to estimate the cost and associated burden to the United States (U.S.) healthcare system, if such a change were adopted in the U.S. Methods: This study is a retrospective review of all patients age 14 years or older who were admitted to one of eight different hospitals located throughout the U.S. with acetaminophen exposures during a five and a half year span, encompassing from 1 January 2008 to 30 June 2013. Those patients who would be treated with the revised nomogram, but not the current nomogram were included. The cost of such treatment was extrapolated to a national level. Results: 139 subjects were identified who would be treated with the revised nomogram, but not the current nomogram. Extrapolating these numbers nationally, an additional 4507 (95{\%}CI 3641–8751) Americans would be treated annually for acetaminophen toxicity. The cost of lowering the treatment threshold is estimated to be $45 million (95{\%}CI 36,400,000–87,500,000) annually. Conclusions: Adopting the revised treatment threshold in the U.S. would result in a significant cost, yet provide an unclear clinical benefit.",
keywords = "acetaminophen, Cost, paracetamol, Rumack–Matthew nomogram, toxicity",
author = "Michael Levine and Sam Stellpflug and Pizon, {Anthony F.} and Stephen Traub and Rais Vohra and Timothy Wiegand and Nicole Traub and David Tashman and Shoma Desai and Jamie Chang and Dhruv Nathwani and Stephen Thomas",
year = "2017",
month = "7",
day = "3",
doi = "10.1080/15563650.2017.1291945",
language = "English (US)",
volume = "55",
pages = "569--572",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Estimating the impact of adopting the revised United Kingdom acetaminophen treatment nomogram in the U.S. population

AU - Levine, Michael

AU - Stellpflug, Sam

AU - Pizon, Anthony F.

AU - Traub, Stephen

AU - Vohra, Rais

AU - Wiegand, Timothy

AU - Traub, Nicole

AU - Tashman, David

AU - Desai, Shoma

AU - Chang, Jamie

AU - Nathwani, Dhruv

AU - Thomas, Stephen

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Background: Acetaminophen toxicity is common in clinical practice. In recent years, several European countries have lowered the treatment threshold, which has resulted in increased number of patients being treated at a questionable clinical benefit. Objective: The primary objective of this study is to estimate the cost and associated burden to the United States (U.S.) healthcare system, if such a change were adopted in the U.S. Methods: This study is a retrospective review of all patients age 14 years or older who were admitted to one of eight different hospitals located throughout the U.S. with acetaminophen exposures during a five and a half year span, encompassing from 1 January 2008 to 30 June 2013. Those patients who would be treated with the revised nomogram, but not the current nomogram were included. The cost of such treatment was extrapolated to a national level. Results: 139 subjects were identified who would be treated with the revised nomogram, but not the current nomogram. Extrapolating these numbers nationally, an additional 4507 (95%CI 3641–8751) Americans would be treated annually for acetaminophen toxicity. The cost of lowering the treatment threshold is estimated to be $45 million (95%CI 36,400,000–87,500,000) annually. Conclusions: Adopting the revised treatment threshold in the U.S. would result in a significant cost, yet provide an unclear clinical benefit.

AB - Background: Acetaminophen toxicity is common in clinical practice. In recent years, several European countries have lowered the treatment threshold, which has resulted in increased number of patients being treated at a questionable clinical benefit. Objective: The primary objective of this study is to estimate the cost and associated burden to the United States (U.S.) healthcare system, if such a change were adopted in the U.S. Methods: This study is a retrospective review of all patients age 14 years or older who were admitted to one of eight different hospitals located throughout the U.S. with acetaminophen exposures during a five and a half year span, encompassing from 1 January 2008 to 30 June 2013. Those patients who would be treated with the revised nomogram, but not the current nomogram were included. The cost of such treatment was extrapolated to a national level. Results: 139 subjects were identified who would be treated with the revised nomogram, but not the current nomogram. Extrapolating these numbers nationally, an additional 4507 (95%CI 3641–8751) Americans would be treated annually for acetaminophen toxicity. The cost of lowering the treatment threshold is estimated to be $45 million (95%CI 36,400,000–87,500,000) annually. Conclusions: Adopting the revised treatment threshold in the U.S. would result in a significant cost, yet provide an unclear clinical benefit.

KW - acetaminophen

KW - Cost

KW - paracetamol

KW - Rumack–Matthew nomogram

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=85014534673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014534673&partnerID=8YFLogxK

U2 - 10.1080/15563650.2017.1291945

DO - 10.1080/15563650.2017.1291945

M3 - Article

C2 - 28489461

AN - SCOPUS:85014534673

VL - 55

SP - 569

EP - 572

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 6

ER -